

Quantitative Monographs

Is it easier to be a quant in small-caps?

Equities

Global
Quantitative

Is it easier for quant investors in small-caps?

Over the last ten years it appears that in Europe the classic quantitative strategies would have performed better in the small-cap universe, but in the US large-cap style portfolios would have been more successful.

In Europe small-cap quant strategies are more effective

The breadth of the European small-cap market is much greater so there are more opportunities for investors. Also, classic quant signals seem to have greater predictive power (IC) in European small-caps vs large-caps. These effects offset the greater trading costs in small-caps (under our costs model), making small-cap quant strategies more successful in Europe.

Large-cap quant strategies more successful in the US

The effects of greater breadth and higher ICs are smaller in the US than in Europe, and are not enough to offset the impact of the higher trading costs which US small-cap investors face. This means quant strategies look less attractive in small-cap US.

Claire Jones, CFA

Analyst

claire-c.jones@ubs.com
+44-20-7568 1873

Nick Baltas, PhD

Analyst

nick.baltas@ubs.com
+44-20-7568 3072

Josh Holcroft

Analyst

josh.holcroft@ubs.com
+852-2971 7705

David Jessop

Analyst

david.jessop@ubs.com
+44-20-7567 9882

Josie Gerken, PhD

Analyst

josephine.gerken@ubs.com
+44-20-7568 3560

Paul Winter

Analyst


paul-j.winter@ubs.com
+61-2-9324 2080

Shanle Wu, PhD

Analyst


shanle.wu@ubs.com
+852-2971 7513

Figure 1: European small-caps have greater breadth ...




Source: UBS Quantitative Research

Figure 2: and higher information coefficients ...



Source: UBS Quantitative Research

Figure 3: ... but also higher trading costs than large-caps



Source: UBS Quantitative Research

www.ubs.com/investmentresearch

This report has been prepared by UBS Limited. **ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 17.** The recommendations in this report are based on UBS's proprietary quantitative models. These recommendations are made independently of the recommendations of UBS's fundamental equity research analysts. UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Summary

Investors sometimes ask us if quantitative strategies are more effective in small-cap universes than in large-cap universes. There is some motivation for this idea. Small-cap markets do appear to be less efficient than large-cap markets in some respects. For example, some quantitative signals, such as the earnings announcement drift, seem to have a longer half-life amongst small-caps than large-caps. Theoretically, that should make it easier for quantitative strategies to identify mis-pricings amongst small-cap names, and hence for quant strategies to perform better there than in large-caps.

In this note, we examine some empirical evidence to address this question. We start from the fundamental law of active management which states that:

$$\text{Information ratio} = \text{information coefficient} \times \sqrt{\text{breadth}}$$

This implies that there are two factors which affect the performance of a strategy:

- i) **Information coefficient** (IC) of your signal
- ii) **Breadth** of your universe (how many independent bets there are)

to which we would add a third:

- iii) **Trading costs**

To answer whether it is easier for quantitative investors in small-cap or large-cap universes, we've broken down our analysis into parts based on these three categories.

As you would expect, in both the US and Europe, trading costs are much higher amongst small-cap stocks. This difference in trading costs has narrowed in recent years, but there is still a big gap, which makes it harder for small-cap investors.

The breadth of the small-cap universes is higher in both the US and in Europe, but the difference is much more pronounced in the European universe. The information coefficient of traditional quantitative strategies, like value or price momentum, are typically higher in the small-cap universe than amongst the large-cap names. However, again, we find that this gap is more pronounced in Europe.

In Europe, we find that, overall, the negative impact of the higher trading costs that small-cap investors face is offset by the higher breadth and greater predictive power of traditional quantitative signals in that universe. It appears that, over the last ten years, quantitative investors probably would have been more successful in the small-cap universe.

This did not hold true in the US. There, it appeared that the higher trading costs are not fully offset by higher ICs and higher breadth of the small-cap universe. It seems that over the last ten years, most traditional quantitative investors would probably have done better in large-caps rather than small-caps.

Are quantitative strategies more effective in a small-cap universe?

Small-cap universe = higher trading costs, higher breadth and higher ICs

Some evidence that quant investing has been more effective in European small-caps ...

... but not US small-caps

Data


We consider a European universe and a US universe of stocks. For the European universe we define our size baskets as the European constituents of the Dow Jones small-cap, mid-cap and large-cap indices. For the US, our universe is the S&P 1500, which consists of the S&P 500, the S&P mid-cap 400 and the S&P Small-cap 600.

Europe = European constituents of DJ small, mid and large-cap

US = S&P 500, S&P 400 and S&P 600

Figure 4 shows the distribution of market caps amongst the various universes. The S&P small-cap 600 has a median market cap of around 1bn USD, the mid-cap market cap is typically around 3.4bn and the S&P 500 stocks have a median market cap of roughly 15bn USD. The European universe is slightly narrower than the US universe. The European small-cap stocks have a median market cap of around 2bn USD compared to 6.7bn USD for mid-caps and 24bn USD for large cap stocks.


Figure 4: Box-plots showing the distribution of market-caps of small, mid and large-cap universes



Source: UBS Quantitative Research. Data is as of 30th June 2016. Please note the log scale.

While the number of stocks in the S&P indices is fixed, the number of stocks in the European size baskets can change through time, as Figure 5 illustrates.

Figure 5: Number of stocks in the European size baskets



Source: UBS Quantitative Research


Breadth

The breadth of a universe does not have a standard definition, but we have tried to proxy for breadth in three different ways:

- i) **Average pairwise correlation** of stocks – if all the stocks move together, that suggests low breadth.
- ii) **Diversification ratio**, which is the ratio of the risk of the portfolio assuming no diversification to its actual risk, i.e. $\sum_i \sigma_i w_i / \sqrt{w^T \Sigma w}$ – a lower diversification ratio suggests lower breadth.
- iii) **Absorption ratio**, which is the proportion of the cross-sectional risk which can be explained by the first 10 statistical risk factors – a higher value suggests lower breadth.

Figure 6 shows the average pairwise correlation in each size basket. There is a long-term trend of increasing pairwise correlation in the markets (although this has slipped back somewhat since 2010) but small-cap stocks consistently co-move less than large-cap stocks. This difference is more pronounced in Europe than in the US.


Figure 6: Average pairwise correlation in large-cap and small-cap markets



Source: UBS Quantitative Research, correlation is computed with daily data over the previous quarter

Figure 7 shows the diversification ratios through time and in each universe. This is nearly always higher amongst small-cap stocks than amongst large-cap stocks. This suggests that diversification is having a greater impact amongst small-cap stocks and hence that these names have a higher breadth. However, the gap in diversification ratios between the small-cap and large-cap universes has reduced in recent years, particularly in the US – it appears that the difference in breadth is reducing. This is not surprising given that the average pairwise correlation has increased through time (see Figure 6).


Figure 7: Diversification ratio in large-cap and small-cap markets



Source: UBS Quantitative Research, the diversification ratio is a measure of how much higher the risk would be without the effect of diversification, ratio is estimated using the previous quarter of daily returns.

The absorption ratio measures how effective a simple statistical cross-sectional risk model would be in that universe. A lower value suggests the risk model would be less effective and implies that universe has a higher breadth. As Figure 8 illustrates, it is clear that the small-cap universes tend to have a higher breadth, but the difference is again more clear-cut in Europe than in the US.

Figure 8: Absorption ratio in large-cap and small-cap markets



Source: UBS Quantitative Research, the absorption ratio is the proportion of the cross-sectional risk explained by the first 10 statistical risk factors

In every case, it appears that the small-cap names have greater breadth than the large-cap names, which suggests that there are greater opportunities for small-cap investors, but the difference is much less pronounced in the US.

Small-caps appear to have greater breadth, but the difference is smaller in the US

Costs

There are very different trading costs amongst the small-cap and large-cap universes and this can have a big impact on the performance of investment strategies, but unfortunately, it is difficult to estimate costs exactly. For any number of reasons, different investors face different trading costs and it is hard to give estimates for costs that will be relevant to both small, high frequency investors and to billion dollar funds that trade over the course of weeks or months.

We have tried anyway. We use a very simple costs model to try and estimate the costs faced by investors in each universe back through time¹. While these costs may differ from costs a particular investor faces, the overall analysis, and in particular how our estimated costs change should still be meaningful.

Technical details of our costs model

We use a costs model discussed in Almgren et al's paper *Direct Estimation of Equity Market Impact*, May 2005. They use five key inputs to estimate the cost of a trade:

- i. The **bid-ask spread (BA)**, a direct measure of charges made to the investor to buy or sell
- ii. **Volatility (σ)**, if the stock is more volatile, then the price is more likely to move during execution, which leads to higher costs
- iii. **Order size ($\frac{x}{v}$)** as a proportion of the average daily trading volume (ADV), larger orders tend to have bigger price impacts
- iv. Length of **time (T)** allowed to complete the order, if an investor demands faster execution he will need to pay more for the privilege. For this analysis, we assume all trades are executed over the course of one day.
- v. The **inverse turnover ($\frac{\phi}{v}$)**, which is the inverse of the ADV as a proportion of the shares outstanding. There will typically be less price impact with more liquid companies

They divide the price impact into two categories, permanent and temporary, giving us this model:

Figure 9: Almgren et al's Cost Model

I)	$Permanent\ price\ impact = 0.314 \cdot \sigma \cdot \frac{x}{v} \cdot \left(\frac{\phi}{v}\right)^{0.25}$
II)	$Temporary\ price\ impact = \frac{1}{2} \cdot permanent\ price\ impact + sign(X) \cdot 0.142 \cdot \sigma \cdot \left \frac{x}{v \cdot T}\right ^{0.6}$
III)	$Other\ costs = 0.5 \cdot BA$

Source: Almgren et al, Direct Estimation of Equity Market Impact, May 2005

This is, of course, a simplification. There are many more factors which influence the cost to trade and for institutional investors very large trades will often be block traded, which introduces different dynamics.

Estimated costs through time

As an illustration of the costs investors face in small and large-cap universes we have estimated the median cost of buying a \$250,000 of each stock in a day. Figure 10 and Figure 11 show our estimates in the European and US universes respectively.

As a sanity check, we have also plotted the estimated cost to trade in each region and year discussed in Frazzini, Israel and Moskowitz's 2012 paper "Trading Costs

¹ For a more detailed discussion of trading costs please see our Apr '15 note "[Costs as a style factor](#)"

of Asset Pricing Anomalies"². This is the black line on the charts. Our costs appear comparable.

Figure 10: European cost estimates – how much does it cost to buy \$250,000 of a stock in a day?





Figure 11: US cost estimates – how much does it cost to buy \$250,000 of a stock in a day?



Source: UBS Quantitative Research & "Trading Costs of Asset Pricing Anomalies" by Frazzini A., Israel R. and Moskowitz, T, 2012

The coloured lines show the median estimated cost to buy \$0.25m in each stock in the index in one day, based on our costs model. We have deflated this dollar value back through time by the index price level. We also drop stocks from our estimates where \$0.25m represents more than 30% of ADV. The black line shows the value weighted average cost of trades, either in the International markets (for the European chart) or the US markets (for the US chart) over the course of the year, taken from Frazzini et al.

As expected, the typical trading costs in the small-cap universe are considerably higher than those in the large-cap universe. This is a significant negative for investors considering investing in small-cap names.

The costs in both the small and large-cap universes have fallen considerably over the last 20 years, but have stabilised since 2005. Given this radical shift in costs, most of our subsequent analysis will focus on the previous 10 years.

Figure 12: Estimated trading costs in 2016 for small / mid / large-caps

	US	Europe
Small	20	36
Mid	6	12
Large	2	6

Source: UBS Quantitative Research

² For a summary of this interesting paper, please see our review in the Feb '15 edition of the Academic Research Monitor, "[Smart betas, Factors and Style Investing](#)".

Isolate the effects of breadth and costs

We are considering each of the three possible causes of differences in the performance of quant strategies in the size bands (breadth, costs, information coefficients), but before we move on to the final cause (ICs), we want to examine the effects of breadth and costs in a little more detail. To try and isolate the impact of breadth and costs we have analysed some simulated results.

We create random signals in each universe with a given expected information coefficient and see how portfolios generated with these signals perform. Any differences in the gross performances between size bands show the effect of breadth and any differences in the net performances show the combined effects of breadth and costs.

Here is the algorithm we use for our simulations:

- i. Create an artificial signal³ with a given expected information coefficient.
 - $\text{Signal} = \text{future return} + \text{noise}$
- ii. Create a portfolio using that signal with some simple portfolio construction rules
 - Top 50 names, but with a buffer at top 100 i.e. we only replace a name in the portfolio if it falls out of the top 100 names
 - Equal weighted
 - Rebalanced quarterly
- iii. Simulate the returns to the portfolio, on both a gross and a net basis (where we assume costs based on an initial 50m USD investment).


We run the algorithm 500 times to see the distribution of the gross and net CAPM alphas with different expected ICs.

Figure 13 shows the distribution of the gross CAPM alphas and hence shows the effect of breadth on its own. In Europe, the small-cap portfolio nearly always has a higher CAPM alpha than the large-cap alphas, at every level of IC. In the US, the gap between the CAPM alpha in the two universes is much smaller, with the gap only really opening up at higher levels of IC. This is because there is a much smaller difference in breadth between the US small and large-cap universes.

Effect of breadth

³ For more details about how we create these signals please see the appendix.

Figure 13: Distribution of gross CAPM alpha with different expected ICs




Source: UBS Quantitative Research, our sample time period is Jan 2005 to Dec 2015.

If we repeat the analysis again, but this time incorporating trading costs into our estimates for portfolio performances then we can see the combined effect of breadth and costs. This is shown in Figure 14. In Europe, it looks like the higher costs that small-caps face cancels out the effect of their greater breadth, so that the small-caps and large-caps perform broadly in-line. In the US, where small-caps had only a small lead on a gross basis, the large-caps dominate after costs.

Effects of breadth AND costs

Figure 14: Distribution of net CAPM alpha with different expected ICs



Source: UBS Quantitative Research, our sample time period is Jun 2006 to Jun 2016

Information Coefficients

The last piece of the puzzle is the information coefficients of quantitative investment signals in the small-cap and large-cap universes. We look at 20 of the classic styles used in quantitative investing. These are all factors which are commonly discussed and used in factor screens, including value, growth, momentum, quality and risk styles.

Quantitative Signals


Figure 15: Our styles

Style Family	Style	Style Family	Style
Value	Earnings Yield	Growth	EPS Forecast Growth
	Book Value Yield		Historic earnings growth
	Core EBIT to EV		PEG
	Dividend Yield	Momentum	1 mth Price Momentum
	Free Cash Flow Yield		6 mth Price Momentum
	Core Sales to EV		12 mth Price Momentum
Quality	ROE		Earnings Momentum
	ROIC	Risk	Volatility
	Net Debt To EV		Beta
	Capex to Depn	Size	Market Cap

Source: UBS Quantitative Research

The Information Coefficient (IC) is the correlation between your signal and the future return. A higher IC suggests your style is more reliable and useful as an investment signal. However, be cautious: for some styles, we *want* a negative IC. For example, we typically buy low volatility stocks, so we want low volatility to be associated with outperformance and vice versa.

Figure 16: European Average Quarterly ICs




Source: UBS Quantitative Research, our sample time period is Jun 2006 to Jun 2016. For illustrative purposes only

Taking this directionality into account, it looks like 15 out of our 20 styles had a better average quarterly IC amongst small-cap stocks than amongst large-caps over the last ten years in Europe. Quant signals appear to have been more reliable amongst small-caps here.

Most styles have better ICs amongst European small-caps than European large-caps

Figure 17: US Average Quarterly ICs



Source: UBS Quantitative Research, our sample time period is Jun 2006 to Jun 2016. For illustrative purposes only

As Figure 17 illustrates, it appears that quant signals have had lower ICs in the US than in Europe, in both the small-cap and large-cap universes, over the last ten years. Also, while the average quarterly ICs were typically higher amongst small-caps, the gap between the large-cap and small-caps average ICs is much narrower.

Gap in ICs is narrower in the US

Quantitative strategies

Finally, we examine the performance of quantitative strategies in the small-cap and large-cap universes by building portfolios of stocks by each style.

The portfolios are:


- Long only
- Thirds e.g. top third by earnings yield
- Cap weighted
- Rebalanced quarterly

Create style portfolios

We assume that we start our portfolios with an initial investment of \$50m in June 2006. This is important for our trading costs estimations.

Figure 18 shows that, In Europe, all but two of the strategies would have outperformed in the small-cap universe over the large-cap on a gross basis, but, after costs have been taken into account that drops to 15 out of the 20 strategies.


Figure 18: Europe, CAPM alpha of strategies in small-cap and large-cap universes



Source: UBS Quantitative Research, our sample time period is Jun 2006 to Jun 2016, CAPM alpha is versus the overall benchmark i.e. DJ Europe or S&P 1500. For illustrative purposes only

In the US, as Figure 19 illustrates, the small-cap strategies would not have been as successful. Only half of the small-cap portfolios would have outperformed their large-cap peers on a net basis, and that falls to just 8 out of 20 once we look at the net returns.

Figure 19: US, CAPM alpha of strategies in small-cap and large-cap universes



Source: UBS Quantitative Research, our sample time period is Jun 2006 to Jun 2016, CAPM alpha is versus the overall benchmark i.e. DJ Europe or S&P 1500. For illustrative purposes only

It seems that European quantitative investors would probably have found the small-cap universe easier than the large-caps, over the last ten years, but this would not have been true in the US.

Conclusions

Are there more opportunities for quantitative investors in the small-cap universe? Looking at the historic performances of classic quantitative strategies, it appears that, for Europe small-cap style portfolios would have performed better, but in the US, the large-cap style portfolios would have been more successful.

To understand what is driving this difference we break the performance of quantitative strategies down into three parts: the breadth of the universe, the information coefficient of the signal you use to build your portfolios and the trading costs you face.

For European investors, the greater trading costs which a small-cap investor faces appear to be offset by the greater breadth amongst the small-caps and the higher ICs which the traditional quantitative signals achieved in the small-cap universe. Overall, the majority of the European small-cap styles would have been more effective than their large-cap counterparts.

The US small-cap universe is also broader than the large-cap universe, but only slightly. The ICs of the classic quantitative signals in the small-cap universe do tend to be higher, but again, only slightly. It appears that the effects of greater breadth and higher ICs are smaller in the US than in Europe, and are not enough to offset the impact of the higher trading costs which US small-cap investors face.

Small-cap styles were often more successful in Europe, but in the US large-cap quant styles outperformed.

Performance = breadth + IC + trading costs

In Europe, higher costs are offset by greater breadth and better ICs ...

... but not in the US

Appendix

Generating random signals with a given IC

We define our signal as the sum of the future return and a noise term which is independent and normally distributed with mean zero and variance σ_{noise}^2 :

$$signal_t = r_{t,t+1} + noise_t \text{ where } noise \sim N(0, \sigma_{noise}^2)$$

The correlation between our signal and the future return is:

$$\rho_{r,signal} = \frac{cov(r,signal)}{\sigma_r \sigma_{signal}} = \frac{cov(r,r+noise)}{\sigma_r \sigma_{r+noise}} = \frac{\sigma_r^2}{\sigma_r \sqrt{\sigma_r^2 + \sigma_{noise}^2}}$$

If we set the variance of the noise term to be:

$$\sigma_{noise}^2 = \frac{\sigma_r^2(1-x^2)}{x^2}$$

Then the correlation simplifies down to x.

So, by careful choice of the variance of noise term, we can create a random signal with a given expected Information Coefficient (here called x).

UBS Equity Quantitative Research

Team

UK – London

Nick Baltas	+44-20-7568 3072
Maylan Cheung	+44-20-7568 4477
Ian Francis	+44-20-7568 1872
Josie Gerken	+44-20-7568 3560
Simon Iley	+44-20-7568 6327
David Jessop	+44-20-7567 9882
Claire Jones	+44-20-7568 1873
Manoj Kothari	+44-20-7568 1997
Simon Stoye	+44-20-7568 1876
Christine Vargas	+44-20-7568 2409

Hong Kong

Josh Holcroft	+852-2971 7705
Shanle Wu	+852-2971 7513

Australia– Sydney

Oliver Antrobus	+61-3-9242 6467
Luke Brown	+61-2-9324 3620
Pieter Stoltz	+61-2-9324 3779
Paul Winter	+61-2-9324 2080

Research Publications

Monographs, Keys and Q-Series		Academic Research Monitor	
Title	Date	Topic	Date
Follow the smart money	Jul-16	Portfolio Construction and Overfitting	Jun-16
How can supply chains improve earnings visibility?	Jul-16	UBS Equity Markets Conference	May-16
Where are the attractive dividend paying stocks?	Mar-16	European Quantitative Conference 2015 Highlights	Apr-16
Why does increasing volatility matter?	Feb-16	Does Oil matter for Equity Markets?	Mar-16
What crowded positions are bubbling up in equity markets	Feb-16	Low Risk Investing	Feb-16
What happened to Value, and when will it return?	Jan-16	Value Investing	Dec-15
Who benefits from automation?	Nov-15	Analyst Forecasts and Measuring Distance	Nov-15
The Spectre of Equity-Bond allocation	Nov-15	UBS Market Microstructure Conference	Oct-15
Dynamic Asset Allocation	Nov-15	Equity Risk Premium Forecasting and Market Timing	Sep-15
How will demographics shape investing for the next ten years?	Nov-15	Behavioural Investing Patterns	Jul-15
Surfing the macro wave	Sep-15	Quality and Size Investing	May-15
Why blame Risk-parity and CTAs?	Sep-15	European Quantitative Conference 2015 Highlights	Apr-15
Bonds are better: asset allocation in target dated funds	Sep-15	Smart Beta, Factors and Style Investing	Feb-15
Low-Risk Investing: perhaps not everywhere	Jul-15	Momentum-Investing	Jan-15
Cost efficient trading with time varying alphas	Jul-15	Investment Strategies & Textual Analysis Signals	Dec-14
The Madness of Crowds	Jul-15	Commodity Risk & Institutional Investing Habits	Nov-14
Lessons from Behavioural Finance	Jul-15	Index Membership, Investor (in)attention to News & Spurious Correlations	Sep-14
A Closer look at the Trend Factor	Jun-15	Forecasting the Equity Risk Premium	Aug-14
Understanding Size Investing	Jun-15	Implied Cost of Capital & Shorting Premium	Jun-14
Safe Dividends in Times of Financial Repression	Jun-14	European Quantitative Conference 2014 Highlights	May-14
Costs as a Style Factor	Apr-15	Trend Following	Mar-14
Cross-Asset Seasonality	Mar-15	Factor investing & Quality	Feb-14
Extending our quality model to financials	Mar-15	Quality & Gross Profitability	Jan-14
Where are the crowded trades?	Jan-15	Minimum variance: valuation, concentration and exchange rates	Dec-13
Stock Selection using Machine Learning	Jan-15	Liquidity & back test overfitting	Oct-13
Investing in Growth	Jan-15	News and its effect on asset prices	Sep-13
Harvesting Cross-Asset Value	Dec-14	Asset pricing & skewness	Aug-13
How to avoid 'Torpedoes'	Nov-14	Timing momentum & risk parity	Jul-13
PAS User Guides			
Quick Reference Guide	Nov-15	Advanced Analysis	Oct-12
Risk Parity and Composite Assets	Jan-15	PAS Macros	Feb-16
Introduction to the UBS Portfolio Analysis System	Jan-15	Risk Models	Nov-11
Long-Short Analysis	Jan-15	UBS Hybrid Risk Model	Dec-10
Installation	May-14	Quick Portfolio Analysis	Jul-10
Reports	Apr-14	Portfolio Analysis	Jun-10
Risk Parity	Feb-13	Optimisation with PAS	Jun-10

Required Disclosures

This report has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 22 August 2016 02:58 PM GMT.

Analyst Certification: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage ¹	IB Services ²
Buy	FSR is > 6% above the MRA.	47%	32%
Neutral	FSR is between -6% and 6% of the MRA.	38%	25%
Sell	FSR is > 6% below the MRA.	15%	21%
Short-Term Rating	Definition	Coverage ³	IB Services ⁴
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%

Source: UBS. Rating allocations are as of 30 June 2016.

1: Percentage of companies under coverage globally within the 12-month rating category.

2: Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3: Percentage of companies under coverage globally within the Short-Term rating category.

4: Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS: **Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES: **UK and European Investment Fund ratings and definitions are:** **Buy:** Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Limited: Claire Jones, CFA; Nick Baltas, PhD; David Jessop; Josie Gerken, PhD. **UBS AG Hong Kong Branch:** Josh Holcroft; Shanle Wu, PhD. **UBS Securities Australia Ltd:** Paul Winter.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

Global Disclaimer

This document has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo and, in certain instances, UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ("the Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on NEO. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:**

Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey.

Poland: Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce.

Russia: Prepared and distributed by UBS Bank (OOO).

Switzerland: Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA).

Italy: Prepared by UBS Limited and distributed by UBS Limited and UBS Limited, Italy Branch. Where an analyst of UBS Limited, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Limited, Italy Branch.

South Africa: Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328).

Israel: This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons.

Saudi Arabia: This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37.

Dubai: The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates.

United States: Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a "non-US affiliate") to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.

Canada: Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration.

Mexico: This report has been distributed and prepared by UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is an affiliate of UBS AG. This document is intended for distribution to institutional or sophisticated investors only. Research reports only reflect the views of the analysts responsible for the reports. Analysts do not receive any compensation from persons or entities different from UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, or different from entities belonging to the same financial group or business group of such. For Spanish translations of applicable disclosures, please see www.ubs.com/disclosures.

Brazil: Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities.

Hong Kong: Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch.

Singapore: Distributed by UBS Securities Pte. Ltd. [MCI (P) 018/09/2015 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289).

Japan: Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant.

Australia: Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecs-research-fsg.

New Zealand: Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor.

Korea: Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch.

Malaysia: This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients.

India: Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, NSE (Currency Derivatives Segment) INE230951431, BSE (Capital Market Segment) INB010951437; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2016. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

